Iovance Biotherapeutics Inc
SWB:2LB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Iovance Biotherapeutics Inc
SWB:2LB
|
US |
Intrinsic Value
The intrinsic value of 
Iovance Biotherapeutics Inc (2LB) under the Base Case is 5.72 EUR per share.
Compared with the current market price of 8.34 EUR, the stock appears
Overvalued by 31% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Iovance Biotherapeutics Does
Iovance Biotherapeutics develops cell therapies for cancer, with a focus on tumor-infiltrating lymphocyte, or TIL, treatments. These are personalized medicines made from a patient’s own immune cells, expanded in the lab, and given back as a treatment that can help the body attack tumors. The company’s main product work centers on making and commercializing these therapies for patients with certain solid tumors.
- Headquarters
- United States of America US
- Employees
- 975
- IPO date
- Jun 20, 2008
Revenue & Expenses Breakdown
Iovance Biotherapeutics Inc
Earnings Waterfall
Iovance Biotherapeutics Inc
The intrinsic value for Iovance Biotherapeutics Inc (2LB) under the Base Case is 5.72 EUR.
Compared with the current market price of 8.34 EUR, the stock appears Overvalued by 31% .